Table 2.
Distribution of demographic and clinical characteristics in group II
| Demographic and clinical features | n |
Frequency of CIK cells immunotherapy, n (%) |
χ2 | P | |||
| 0 | 1-10 | 11-25 | > 25 | ||||
| Sex | |||||||
| Men | 122 | 62 (76.5) | 39 (84.8) | 13 (86.7) | 8 (57.1) | 5.573 | 0.134 |
| Women | 34 | 19 (23.5) | 7 (15.2) | 2 (13.3) | 6 (42.9) | ||
| Age (yr) | |||||||
| ≤ 45 | 14 | 7 (8.6) | 5 (10.9) | 1 (6.6) | 1 (7.1) | 1.153 | 0.979 |
| 45 < age ≤ 60 | 71 | 36 (44.4) | 20 (43.5) | 7 (46.7) | 8 (57.1) | ||
| > 60 | 71 | 38 (47.0) | 21 (45.6) | 7 (46.7) | 5 (35.8) | ||
| Tumor sitea | |||||||
| Gastric cardia | |||||||
| Yes | 58 | 30 (37.0) | 17 (37.0) | 5 (33.3) | 6 (42.9) | 0.290 | 0.962 |
| No | 98 | 51 (63.0) | 29 (63.0) | 10 (66.7) | 8 (57.1) | ||
| Gastric body | |||||||
| Yes | 64 | 35 (43.2) | 19 (41.3) | 5 (33.3) | 5 (35.7) | 0.691 | 0.875 |
| No | 92 | 46 (56.8) | 27 (58.7) | 10 (66.7) | 9 (64.3) | ||
| Gastric antrum | |||||||
| Yes | 36 | 17 (21.0) | 10 (21.7) | 4 (26.7) | 5 (35.7) | 1.614 | 0.656 |
| No | 120 | 64 (79.0) | 36 (78.3) | 11 (73.3) | 9 (64.3) | ||
| Tumor sizec (cm) | |||||||
| < 5 | 76 | 43 (59.7) | 17 (45.9) | 7 (58.3) | 9 (81.8) | 4.834 | 0.184 |
| ≥ 5 | 56 | 29 (40.3) | 20 (54.1) | 5 (41.7) | 2 (18.2) | ||
| Histological typec | |||||||
| Differentiated | 52 | 28 (35.4) | 12 (30.0) | 6 (40.0) | 6 (50.0) | 1.760 | 0.624 |
| Poorly-differentiated | 94 | 51 (64.6) | 28 (70.0) | 9 (60.0) | 6 (50.0) | ||
| Invasionc | |||||||
| Yes | 112 | 55 (76.4) | 38 (90.5) | 10 (90.9) | 9 (81.8) | 4.226 | 0.238 |
| No | 24 | 17 (23.6) | 4 (9.5) | 1 (9.1) | 2 (18.2) | ||
| Lymph node metastasisc | |||||||
| Yes | 100 | 55 (76.4) | 31 (75.6) | 7 (58.3) | 7 (63.6) | 2.371 | 0.499 |
| No | 36 | 17 (23.6) | 10 (24.4) | 5 (41.7) | 4 (36.4) | ||
| Relapse | |||||||
| Yes | 98 | 58 (71.6) | 31 (67.4) | 8 (53.3) | 1 (7.1) | 15.633 | 0.0004 |
| No | 58 | 23 (28.4) | 15 (32.6) | 7 (46.7) | 13 (92.9) | ||
| Pathological grade | |||||||
| 1 | 2 | 1 (1.2) | 1 (2.2) | 0 (0.0) | 0 (0.0) | 2.976b | 0.3953 |
| 2 | 27 | 18 (22.2) | 8 (17.4) | 0 (0.0) | 1 (7.1) | ||
| 3 | 92 | 44 (54.3) | 25 (54.4) | 12 (80.0) | 11 (78.6) | ||
| 4 | 35 | 18 (22.2) | 12 (26.0) | 3 (20.0) | 2 (14.3) | ||
| Tumor stage | |||||||
| I | 14 | 9 (11.1) | 3 (6.5) | 0 (0.0) | 2 (14.2) | 13.66b | 0.0386 |
| II | 22 | 23 (28.4) | 3 (6.5) | 1 (6.7) | 6 (42.9) | ||
| III | 102 | 38 (46.9) | 34 (73.9) | 13 (86.7) | 6 (42.9) | ||
| IV | 18 | 11 (13.6) | 6 (13.1) | 1 (6.6) | 0 (0.0) | ||
a
Tumor sites in some cases were repeated;
b
Because the theoretical value is less than 1, χ2 was performed for patients who received cytokine-induced killer (CIK) cells immunotherapy at the frequencies of 11-25 and > 25, and for those who underwent CIK cells immunotherapy at the frequencies of 1-10, 11-25 and > 25;
c
Missed cases.